C&M Health Law

JUNE 15, 2021

This article was originally published in Corporate Compliance Insights. bribery, fraud, misuse). Health Insurance Portability and Accountability Act (HIPAA) can present several areas of exposure. Significant due diligence processes were established for third parties to prevent bribery and other ethical violations.

Due Diligence 40

Due Diligence Licensing Informed Consent HIPAA 40

Hall Render

NOVEMBER 1, 2023

This Safe Harbor Policy (“Policy”) is aimed at incentivizing acquiring companies to identify and timely disclose misconduct discovered during the due diligence and post-acquisition integration process. Transactions that might have been abandoned or restructured due to the discovery of misconduct can now potentially move forward.

Due Diligence 40

Due Diligence Compliance Fraud 40

Provider Trust

MAY 18, 2022

What the HHS-OIG says about vendor compliance. OIG may exclude the provider if certain circumstances regarding the ownership are present. However, healthcare receives federal funding, and thus OFAC is an additional sanction list that you should add to your vendor compliance plan/program. Case Study: S. Martino-Fleming v.

Compliance 52

Compliance Due Diligence Medicaid Medicaid 52

Hall Render

JANUARY 11, 2023

The Tool presents developers of mobile health apps with a series of questions to help them understand which federal laws and regulations may apply. The Tool does not present a comprehensive list of laws and regulations that may apply to mobile health apps. Regulatory Landscape. Practical Takeaways.

Compliance 40

Compliance HIPAA FDA Due Diligence 40

Healthcare Law Blog

FEBRUARY 2, 2023

healthcare compliance and reimbursement), and sometimes tax and employee benefits. From a buyer’s perspective, the LOI should reserve for additional items that may be discovered through diligence. However, even in non-JV acquisitions, negotiating the LOI presents opportunities for both parties to think creatively and add value.

Due Diligence 52

Due Diligence Fraud Compliance 52

Verisys

JULY 13, 2023

How to Tackle Pharma’s 3 Biggest Compliance Risks Head-On with Verisys How often have you started at a new organization and heard these phrases? “ Some companies make decisions based on compliance standards and optics, while others may be more lax. Clinical trial compliance can offer unique challenges for pharmaceutical companies.

Compliance 52

Compliance Due Diligence Pharmaceutical Industry Fraud 52